XML 63 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Benefit Plans (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Payment Arrangement, Activity
The maximum number of shares of the Company's common stock reserved for issuance over the term of the Plans, shares outstanding under the Plans, and shares remaining under the Plans at December 31, 2022 and 2021, respectively, were as follows:
December 31, 2022Shares Authorized Under PlansShares Outstanding Under PlansShares Remaining Under Plans
2014 Plan54,402,264 36,378,558 N/A
2020 Plan31,884,272 29,805,319 242,473 
2020 MIP33,426,983 30,084,285 — 
Inducement Plan11,000,000 11,000,000 — 
December 31, 2021Shares Authorized Under PlansShares Outstanding Under PlansShares Remaining Under Plans
2014 Plan54,402,264 41,905,875 N/A
2020 Plan30,641,401 6,690,048 23,442,323 
2020 MIP33,426,983 33,426,983 — 
Schedule of Summary of Stock-Based Compensation Cost
Compensation cost presented within Salaries and benefits within the accompanying Consolidated Statements of Operations and Comprehensive Loss were as follows:
Years ended December 31,202220212020
(in thousands)
Stock options$3,445 $7,998 $7,078 
RSUs75,312 65,514 — 
PRSUs85,270 89,930 — 
ESPP278 281 — 
Total compensation cost recognized for stock-based compensation plans$164,305 $163,723 $7,078 
Schedule of Assumptions to Estimate Fair Value of Stock Options on Weighted Average Basis
The assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2021 and December 31, 2020, respectively, were as follows:
Years ended December 31,20212020
Weighted-average risk-free interest rate1.06 %0.84 %
Expected term (in years)6.064.68
Expected volatility37.74 %34.66 %
Expected dividend yield— — 
Schedule of Stock Option Activity
A summary of option activity under the 2020 Plan during the year ended December 31, 2022, was as follows:
Number of optionsWeighted-average exercise price
Outstanding, January 1, 2022
1,753,799 $8.88 
Granted during 2022
— — 
Exercised— — 
Forfeited(388,977)8.88 
Outstanding, December 31, 2022
1,364,822 $8.88 
A summary of option activity under the 2014 Plan during the year ended December 31, 2022, was as follows:
Number of optionsWeighted-average exercise price
Outstanding, January 1, 2022
31,155,742 $2.35 
Granted during 2022
— — 
Exercised(4,367,985)0.13 
Forfeited(1,156,072)1.85 
Outstanding, December 31, 2022
25,631,685 $2.69 
Schedule of Summary of Total RSU activity
A summary of total RSU activity is presented below:
Number of RSUsWeighted-average grant date fair value per share
Outstanding, January 1, 2021
— $— 
Granted during 2021
22,031,869 14.34 
Released(639,752)6.64 
Forfeited(97,276)8.42 
Outstanding, December 31, 2021
21,294,841 $14.60 
Outstanding, January 1, 2022
21,294,841 $14.60 
Granted during 2022
34,706,132 2.45 
Released(4,656,884)14.09 
Forfeited(1,726,890)5.12 
Outstanding, December 31, 2022
49,617,199 $6.48 
Schedule of Weighted Average Grant Date Fair Value of Performance Restricted Stock Units The grant date fair value of Market PRSUs was determined using a Monte Carlo simulation model that incorporated multiple valuation assumptions, including the probability of achieving the specified market condition and the following assumptions:
Year ended December 31, 2022
Expected volatility (1)
40.7 %
Risk-free interest rate (2)
0.5 
Dividend yield (3)
— 
(1) Expected volatility is based on a blend of peer group company historical data adjusted for the Company's leverage.
(2) Risk-free interest rate based on U.S. Treasury yields with a term equal to the remaining Performance Period as of the grant date.
(3) Dividend yield was assumed to be zero as the Company does not anticipate paying dividends.
Schedule of Total Performance Restricted Stock Units
A summary of PRSU activity is presented below:
Number of PRSUsWeighted-average grant date fair value per share
Non-vested, January 1, 2021
— $— 
Granted during 2021
27,818,524 9.58 
Non-vested at December 31, 2021
27,818,524 $9.58 
Non-vested, January 1, 2022
27,818,524 $9.58 
Granted during 2022
2,405,281 1.38 
Vested(13,264)8.90 
Forfeited(265,306)9.11 
Non-vested at December 31, 2022
29,945,235 $8.92 
Schedule of Assumptions Used in ESPP Fair Value Determination
The assumptions that the Company used in the Black-Scholes option-pricing model to determine the fair value of the purchase rights under the ESPP for the year ended December 31, 2022, is as follows:

Year ended December 31, 2022
Weighted-average risk-free interest rate467.0 %
Expected term (in years)0.49
Expected volatility78.4 %